Clinical Trial Update: Bridging Study of L059 (Levetiracetam) in Patients With Epilepsy by Double Blind Method [Phase 2]

View source ↗

Summary

A Phase 2 double-blind bridging study of L059 (levetiracetam) in patients with epilepsy has completed, reporting results from the Phase 2 trial.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy

Drugs mentioned

• Levetiracetam (L059) (levetiracetam)

Snippet

Sponsor: UCB Pharma | Conditions: Epilepsy | Phase 2 | Status: COMPLETED